Juno Therapeutics (NASDAQ: JUNO) recently received a number of ratings updates from brokerages and research firms:

  • 8/7/2017 – Juno Therapeutics was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $28.47 price target on the stock.
  • 8/7/2017 – Juno Therapeutics had its price target raised by analysts at Morgan Stanley from $26.00 to $27.00. They now have an “equal weight” rating on the stock.
  • 8/3/2017 – Juno Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for the global development and commercialization of immunotherapies is encouraging. Juno’s shares outperformed the Medical-Biomed/Genetics industry so far this year. However, the company recently suffered a huge setback as it discontinued the development of cancer candidate, JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”
  • 7/31/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $28.85 price target on the stock.
  • 7/24/2017 – Juno Therapeutics was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $28.85 price target on the stock.
  • 7/17/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $28.85 price target on the stock.
  • 7/11/2017 – Juno Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/11/2017 – Juno Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $32.00 price target on the stock. According to Zacks, “Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for the global development and commercialization of immunotherapies is encouraging. Juno’s shares outperformed the Medical-Biomed/Genetics industry so far this year. However, the company recently suffered a huge setback as it discontinued the development of cancer candidate, JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”
  • 7/10/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $28.85 price target on the stock.
  • 7/5/2017 – Juno Therapeutics was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for the global development and commercialization of immunotherapies is encouraging. Juno’s shares outperformed the Medical-Biomed/Genetics industry so far this year. However, the company recently suffered a huge setback as it discontinued the development of cancer candidate, JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters.”
  • 7/4/2017 – Juno Therapeutics was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $28.85 price target on the stock.
  • 6/27/2017 – Juno Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/26/2017 – Juno Therapeutics was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $28.85 price target on the stock.
  • 6/20/2017 – Juno Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/20/2017 – Juno Therapeutics was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $27.60 price target on the stock.
  • 6/20/2017 – Juno Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $34.00 price target on the stock.
  • 6/12/2017 – Juno Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 6/10/2017 – Juno Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Juno Therapeutics, Inc. (NASDAQ:JUNO) traded down 4.90% during trading on Tuesday, hitting $28.90. 1,213,190 shares of the stock traded hands. The stock’s market cap is $3.01 billion. The stock has a 50 day moving average price of $28.51 and a 200-day moving average price of $24.26. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $35.04.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period in the previous year, the business earned ($0.64) EPS. Juno Therapeutics’s revenue for the quarter was down 22.8% compared to the same quarter last year. On average, analysts anticipate that Juno Therapeutics, Inc. will post ($3.05) EPS for the current fiscal year.

In related news, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total value of $216,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total transaction of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. Insiders sold a total of 8,041,500 shares of company stock worth $217,230,360 in the last three months. 15.26% of the stock is owned by corporate insiders.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.